argenx SE (MEX:ARGX) Future 3-5Y EPS without NRI Growth Rate : N/A (As of Sep. 27, 2024)

View and export this data going back to 2021. Start your Free Trial

What is argenx SE Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, argenx SE's Future 3-5Y EPS without NRI Growth Rate is N/A.

Competitive Comparison of argenx SE's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, argenx SE's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

argenx SE's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, argenx SE's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where argenx SE's Future 3-5Y EPS without NRI Growth Rate falls into.

argenx SE (MEX:ARGX) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

argenx SE Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of argenx SE's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (MEX:ARGX) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

ARGX:USA ARGNF:USA ARGXb:UK 0QW0:UK 1AEA:Germany 1AEA:Germany 1AE:Germany 1AE:Germany A1RG34:Brazil ARGX:Belgium ARGX:Austria

Address

Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB

Website

https://www.argenx.com

Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.